Reconsideration under 37 C.F.R. § 1.111
Page 2 of 12

## AMENDMENTS TO THE CLAIMS

1. (Amended) A method for the removal of cholesterol, triglycerides and other lipids from animal plasma, serum, or other suitable blood fraction containing apolipoproteins, as a discontinuous flow system, said method comprising connecting a subject to a device for withdrawing blood, withdrawing blood containing blood cells from the subject, separating said fraction from the blood cells and mixing with a solvent mixture which extracts said lipids from the fraction but which does not extract said apolipoproteins from the fraction, after which the delipidated fraction is recombined with the blood cells and returned to the subject, such that the solvent extraction step is carried out separately and remote from the subject while the subject is not still connected to the device for withdrawing blood [frown] from the subject, wherein the extraction solvent is removed from the delipidated fraction by mixing the delipidated fraction with an absorbent specific for the extraction solvent and wherein the absorbent does not remove said apolipoproteins from the [delipilidated] delipidated fraction being returned to the subject.

- A method as defined in claim 1, wherein the extraction solvent is substantially removed from the delipidated fraction by washing with a second solvent.
- A method as defined in claim 2, wherein the delipidated fraction is washed four times.

Reconsideration under 37 C.F.R. § 1.111 Page 3 of 12

A method as defined in claim 2, wherein the second solvent is diethyl ether.

5. A method as defined in claim 1, wherein the absorbent is contained in the

pores of sintered spheres.

6. A method as defined in claim 5, wherein the sintered spheres are about 2 mm

to 5 mm in diameter and the pores of the spheres are less than 50 .ANG. in diameter.

7. A method as defined in claim 1, wherein the absorbent is a macroporous

polymeric bead for absorbing organic molecules from an aqueous solution.

8. A method as defined in any one of claim 1, wherein the absorbent is held in a

chamber which is adapted to allow the delipidated fraction to pass through or over the

absorbent at least twice.

A porous sintered sphere for use in a method as defined in claim 1, said sphere

containing an absorbent in its pores.

10. A sintered sphere as defined in claim 9, wherein the absorbent is a

macroporous polymeric bead for absorbing organic molecules from an aqueous solution.

Reconsideration under 37 C.F.R. § 1.111

Page 4 of 12

A method of changing the blood rheology of an animal with impaired blood 11.

circulation whereby the plasma, serum or other suitable blood fraction of the animal has been

treated by a method as defined in claim 1.

A method for rapid regression of coronary atherosclerosis in an animal 12.

whereby the plasma, serum or other suitable blood fraction from the animal is treated by a

method as defined in claim 1.

A method of removing excessive adipose tissue from an animal whereby the

plasma, serum or other suitable blood fraction from the animal is treated by a method as

defined in claim 1.

A method of removing fat soluble toxins from an animal whereby the plasma, 14.

serum or other suitable blood fraction from the animal is treated by a method as defined in

claim 1.

A method of changing the blood rheology of an animal whereby the plasma or 15.

serum of the animal is exchanged for non-autologous plasma or serum wherein said non-

autologous plasma or serum has been treated by a method as defined in of claim 1.

Reconsideration under 37 C.F.R. § 1.111

Page 5 of 12

A method of rapidly regressing coronary atherosclerosis in an animal whereby 16.

the plasma or serum of the animal is exchanged for non-autologous plasma or serum wherein

said non-autologous plasma or serum has been treated by a method as defined in claim 1.

A method of removing excessive adipose tissue from an animal whereby the 17.

plasma or serum of the animal is exchanged for non-autologous plasma or serum wherein

said non-autologous plasma or serum has been treated by a method as defined in claim 1.

A method of removing fat soluble toxins from an animal whereby the plasma 18.

or serum of the animal is exchanged for non-autologous plasma or serum wherein said non-

autologous plasma or serum has been treated by a method as defined in claim 1.

A method for the removal of cholesterol, triglycerides and other lipids from 19.

animal plasma, serum, or other suitable blood fraction containing apolipoproteins, a

discontinuous flow system, said method comprising connecting a subject to a device for

withdrawing blood, withdrawing blood containing blood cells from the subject, separating

said fraction from the blood cells and mixing with a solvent mixture which extracts said lipids from the fraction but which does not extract said apolipoproteins from the fraction,

after which the delipidated fraction is is recombined with the blood cells and returned to the

subject such that the solvent extraction step is carried out separately and remote from the

U.S. Serial No. 09/879,002 Filed: June 12, 2001

Reply and Request for Reconsideration under 37 C.F.R. § 1.111

Page 6 of 12

subject while the subject is not still connected to the device for withdrawing blood from the

subject, wherein the solvent extraction step comprises:

(a) mixing the solvent mixture containing the fraction with beads, said beads being of

a density substantially mid-way between the density of the fraction and the density of the

solvent mixture; and

(b) isolating the thus delipidated fraction-containing phase.

A method as defined in claim 19, wherein the beads contain entrapped air to 20.

obtain the density substantially midway between the density of the fraction and the density of

the solvent mixture.

A method as defined in claim 20, wherein the density of the beads is about 0.9 21.

g/ml.

22. A batch method for removing lipids from a volume of animal or human

plasma, serum, or other suitable blood fraction containing apolipoproteins comprising:

providing the volume of animal or human plasma, serum, or other suitable blood

fraction;

admixing the plasma, serum, or other suitable blood fraction with an extraction

solvent which extracts the lipids from the plasma, serum, or other suitable blood fraction

without extracting the apolipoproteins to form a delipidated fraction;

U.S. Serial No. 09/879,002 Filed: June 12, 2001 Reply and Request for Reconsideration under 37 C.F.R. § 1.111 Page 7 of 12

introducing an absorbent to the delipidated fraction to substantially remove the extraction solvent from the plasma, serum, or other suitable blood fraction; and

separating the absorbent from the delipidated fraction to form a apolipoprotein containing delipidated fraction.

- 23. A batch method as claimed in claim 22, wherein the extraction solvent is substantially removed from the delipidated fraction by washing at least once with a second solvent.
- 24. A batch method as claimed in claim 22, wherein the extraction solvent is substantially removed from the delipidated fraction by washing a plurality of times with a second solvent.
- 25. A batch method as claimed in claim 23, wherein the second solvent is diethyl ether.
- 26. A batch method as claimed in claim 22, wherein the absorbent is disposed in the pores of sintered spheres.
- 27. A batch method as claimed in claim 26, wherein the pores of the sintered spheres are less than 50 Å in diameter.
- 28. A batch method as claimed in claim 22, wherein the absorbent is a macroporous polymeric bead for absorbing organic molecules from an aqueous solution.
- 29. A batch method as claimed in claim 22, wherein the absorbent is held in a chamber which is adapted to allow the delipidated fraction to pass through or over the absorbent at least twice.

U.S. Serial No. 09/879,002 Filed: June 12, 2001 Reply and Request for Reconsideration under 37 C.F.R. § 1.111 Page 8 of 12

- 30. A batch method as claimed in claim 22, further comprising:
- mixing the apolipoprotein containing delipidated fraction with blood cells derived from an animal or a human to form a treated blood.
  - 31. A batch method as claimed in claim 30, further comprising: introducing the treated blood into the blood stream of an animal or a human, wherein

the apolipoprotein containing delipidated fraction and the blood cells are respectively autologous or non-autologous to the animal or human.

- 32. A batch method as claimed in claim 22, further comprising:
- introducing the apolipoprotein containing delipidated fraction into the blood stream of an animal or a human wherein the apolipoprotein containing delipidated fraction is autologous or non-autologous to the animal or human.
- 33. A method of changing the blood rheology of an animal or a human with impaired blood circulation whereby the plasma, serum, or other suitable blood fraction of the animal or the human has been treated by a method as claimed in claim 31.
- 34. A method for rapid regression of coronary atherosclerosis in an animal or a human whereby the plasma, serum, or other suitable blood fraction from the animal or human is treated by a method as claimed in claim 31.
- 35. A method of removing excessive adipose tissue from an animal or a human whereby the plasma, serum or other suitable blood fraction from the animal or human is treated by a method as claimed in claim 31.

U.S. Serial No. 09/879,002
Filed: June 12, 2001
Reply and Request for
Reconsideration under 37 C.F.R.§ 1.111
Page 9 of 12

- 36. A method of removing fat soluble toxins from an animal or a human whereby the plasma, serum or other suitable blood fraction from the animal or human is treated by a method as claimed in claim 31.
- 37. A method of changing the blood rheology of an animal or a human whereby the plasma or serum of the animal or human is exchanged for plasma or serum which has been treated by a method as claimed in claim 32.
- 38. A method of rapidly regressing coronary atherosclerosis in an animal or a human whereby the plasma or serum of the animal or human is exchanged for plasma or serum which has been treated by a method as claimed in claim 32.
- 39. A method of removing excessive adipose tissue from an animal or a human whereby the plasma or serum of the animal is exchanged for plasma or serum which has been treated by a method as claimed in claim 32.
- 40. A method of removing fat soluble toxins from an animal or a human whereby the plasma or serum of the animal or human is exchanged for plasma or serum which has been treated by a method as claimed in claim 32.
- 41. (Amended) A batch method for removing lipids from a volume of animal or human plasma, serum, or other suitable blood fraction comprising:

providing the volume of animal or human plasma, serum, or other suitable blood fraction;

admixing the plasma, serum, or other suitable blood fraction with an extraction solvent selected from hydrocarbons, ethers, alcohols, esters, amines, or mixtures thereof

U.S. Serial No. 09/879,002 Filed: June 12, 2001 Reply and Request for Reconsideration under 37 C.F.R. § 1.111 Page 10 of 12

which extracts the lipids from the plasma, serum, or other suitable blood fraction to form a delipidated fraction;

introducing an absorbent to the delipidated fraction to substantially remove the solvent from the plasma, serum, or other suitable blood fraction; and

separating the absorbent from the delipidated fraction to form a delipidated fraction.

- 42. A method as claimed in claim 41, wherein the extraction solvent comprises a mixture of an alcohol and an ether.
- 43. A method as claimed in claim 42, wherein the extraction solvent comprises a butanol.
- 44. A method as claimed in claim 41, wherein the extraction solvent comprises butan-1-ol or butan-2-ol.
- 45. A method as claimed in claim 41, wherein the extraction solvent comprises an ether.
- 46. A method as claimed in claim 41, wherein the extraction solvent comprises disopropyl ether or propyl ether.
- 47. A method as claimed in claim 41, wherein the extraction solvent comprises 1-butanol and di-isopropyl ether.